Context Therapeutics (CNTX) said Tuesday it dosed the first patient in the phase 1 study of CTIM-76, its lead drug candidate targeting Claudin 6-positive gynecologic and testicular cancers.
Initial data from the trial is expected to be released in H1 2026, the company said.
The phase 1 trial seeks to evaluate the safety and efficacy of CTIM-76 in patients with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancer.
Up to 70 patients will be enrolled in the phase 1 trial to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity, including response rate, duration, and disease control, the company said.
Shares of Context Therapeutics were up 1% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.